'Chang­ing the whole game of drug dis­cov­ery': Leg­endary R&D vet Roger Perl­mut­ter leaps back in­to work as a biotech CEO

Roger Perl­mut­ter needs no in­tro­duc­tion to any­one re­mote­ly in­volved in bio­phar­ma. As the R&D chief first at Am­gen and then Mer­ck, he’s built a stel­lar rep­u­ta­tion and a pro­lif­ic ca­reer steer­ing new drugs to­ward the mar­ket for every­thing from can­cer to in­fec­tious dis­eases.

But for years, he’s al­so held a less known ti­tle: sci­ence part­ner at The Col­umn Group, where he’s reg­u­lar­ly con­sult­ed about the var­i­ous ideas the VCs had for new star­tups.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER